165
180
1,596
533,785
  ÇöÀçÁ¢¼ÓÀÚ : 21 (ȸ¿ø 0)
 È¸¿ø¾ÆÀ̵ð :
±×·ì °Ô½ÃÆÇ Á¦¸ñ À̸§ ÀϽÃ
¾Ï¿¹¹æ¼ÒÀ硦 ¼¾ÅÍÈ°µ¿ ¡¦  The 1st CPMDRC Seminar ÃÖ°í°ü¸®ÀÚ 10-05
¾Ï¿¹¹æ¼ÒÀ硦 ÇмúÈ°µ¿  2007 The 1st CPMDRC Seminar ÃÖ°í°ü¸®ÀÚ 10-04
¾Ï¿¹¹æ¼ÒÀ硦 °øÁö»çÇ×  Çü±¤ Çö¹Ì°æ ±³À° ÃÖ°í°ü¸®ÀÚ 09-28
¾Ï¿¹¹æ¼ÒÀ硦 ¼¾ÅÍ´º½º  MRC ½ÇÇè,½Ç½À ±âÀÚÀç ±¸ÀÔ ÃÖ°í°ü¸®ÀÚ 09-28
¾Ï¿¹¹æ¼ÒÀ硦 ¼¾ÅÍ´º½º  ±âÃÊÀÇ°úÇבּ¸¼¾ÅÍ(MRC) ¾÷¹«°ü¸® ±³À° ¹×¡¦ ÃÖ°í°ü¸®ÀÚ 09-20
¾Ï¿¹¹æ¼ÒÀ硦 °øÁö»çÇ×  The 1st CPMDRC Seminar ÃÖ°í°ü¸®ÀÚ 09-20
¾Ï¿¹¹æ¼ÒÀ硦 ¼¾ÅͱÔÁ¤  ¿©ºñ±ÔÁ¤ ÃÖ°í°ü¸®ÀÚ 09-18
¾Ï¿¹¹æ¼ÒÀ硦 speech  2007 The 1st International Conference of¡¦ ÃÖ°í°ü¸®ÀÚ 09-11
¾Ï¿¹¹æ¼ÒÀ硦 puplished  Antiplatelet and Antithrombotic Activity¡¦ ÃÖ°í°ü¸®ÀÚ 09-10
¾Ï¿¹¹æ¼ÒÀ硦 puplished  PKC and cofilin activation affects peri¡¦ ÃÖ°í°ü¸®ÀÚ 09-10
¾Ï¿¹¹æ¼ÒÀ硦 Àη¾缺  ´ëÇпø»ý µî·Ï±Ý Áö¿ø ÃÖ°í°ü¸®ÀÚ 09-10
¾Ï¿¹¹æ¼ÒÀ硦 ¼¾ÅÍ´º½º  ±âÃÊÀÇ°úÇבּ¸¼¾ÅÍ(MRC)ÁöÁ¤ ¼ö¿©½Ä ÃÖ°í°ü¸®ÀÚ 09-10
¾Ï¿¹¹æ¼ÒÀ硦 ¹ßÇ¥³í¹®  Antiplatelet and Antithrombotic Activity¡¦ ÃÖ°í°ü¸®ÀÚ 09-10
¾Ï¿¹¹æ¼ÒÀ硦 °øÁö»çÇ×  ´ëÇпø»ý µî·Ï ¾È³»(MRCÀåÇÐ±Ý °ü·Ã) ÃÖ°í°ü¸®ÀÚ 08-22
¾Ï¿¹¹æ¼ÒÀ硦 ¹ßÇ¥³í¹®  PKCand cofilin activation affects periph¡¦ ÃÖ°í°ü¸®ÀÚ 08-01
óÀ½  ÀÌÀü  7641  7642  7643  ¸Ç³¡